New hATTR Amyloidosis Research Presented at Recent EU Meeting
fill / Pixabay

New hATTR Amyloidosis Research Presented at Recent EU Meeting

According to a story from BioPortfolio, the drug company Alnylam Pharmaceuticals recently presented research findings related to hATTR amyloidosis, a rare disease. The study was presented at the Second European…

Continue Reading New hATTR Amyloidosis Research Presented at Recent EU Meeting

A New Approach to Halting Metastatic Cancer

A recent article in Northwestern's University Health reported that although the survival rate for cancer patients has vastly improved over the past twenty years, the deaths due to metastatic cancer…

Continue Reading A New Approach to Halting Metastatic Cancer
First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study
felixioncool / Pixabay

First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study

According to a story from Benzinga, the biopharmaceutical company Inventiva has recently announced that it has recruited the first patients in a study of biomarkers in Maroteaux-Lamy syndrome. The study…

Continue Reading First Patients Recruited in Maroteaux-Lamy Syndrome Biomarker Study
A Proof-of-Concept Study for an Experimental Hurler Syndrome Treatment is Going Well so Far
sasint / Pixabay

A Proof-of-Concept Study for an Experimental Hurler Syndrome Treatment is Going Well so Far

According to a story from sectorpublishingintelligence.co.uk, the biopharmaceutical company Orchard Therapeutics recently announced the release of some data from an ongoing proof-of-concept study. This special trial is testing the company's…

Continue Reading A Proof-of-Concept Study for an Experimental Hurler Syndrome Treatment is Going Well so Far

CRISPR Gene Editing Promises to Cure 10,000 diseases. Now in Its First Human Clinical Trial. Will it Eventually Deliver?

  Clustered Regularly Interspaced Short Palindromic Repeats is more commonly known as CRISPR. As reported recently in Science News, the CRISPR/Cas9 “molecular scissors” is slated to make its highly anticipated debut…

Continue Reading CRISPR Gene Editing Promises to Cure 10,000 diseases. Now in Its First Human Clinical Trial. Will it Eventually Deliver?
FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug
mohamed_hassan / Pixabay

FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

According to a press release from Maryland-based Viela Bio, the US Food and Drug Administration (FDA) recently agreed to review the Company's Biologics License Application for its neuromyelitis optica spectrum…

Continue Reading FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug
Close Menu